CA3049354A1 - Antagonists of actriib and uses for increasing red blood cell levels - Google Patents

Antagonists of actriib and uses for increasing red blood cell levels Download PDF

Info

Publication number
CA3049354A1
CA3049354A1 CA3049354A CA3049354A CA3049354A1 CA 3049354 A1 CA3049354 A1 CA 3049354A1 CA 3049354 A CA3049354 A CA 3049354A CA 3049354 A CA3049354 A CA 3049354A CA 3049354 A1 CA3049354 A1 CA 3049354A1
Authority
CA
Canada
Prior art keywords
actrilb
polypeptide
amino acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3049354A
Other languages
English (en)
French (fr)
Inventor
Matthew L. Sherman
Jasbir Seehra
Niels Borgstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of CA3049354A1 publication Critical patent/CA3049354A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3049354A 2008-06-26 2009-06-26 Antagonists of actriib and uses for increasing red blood cell levels Abandoned CA3049354A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13336808P 2008-06-26 2008-06-26
US61/133,368 2008-06-26
CA2729054A CA2729054C (en) 2008-06-26 2009-06-26 Antagonists of actriib and uses for increasing red blood cell levels

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2729054A Division CA2729054C (en) 2008-06-26 2009-06-26 Antagonists of actriib and uses for increasing red blood cell levels

Publications (1)

Publication Number Publication Date
CA3049354A1 true CA3049354A1 (en) 2009-12-30

Family

ID=41445146

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3049354A Abandoned CA3049354A1 (en) 2008-06-26 2009-06-26 Antagonists of actriib and uses for increasing red blood cell levels
CA2729098A Active CA2729098C (en) 2008-06-26 2009-06-26 Antagonists of activin-actriia and uses for increasing red blood cell levels
CA2729054A Active CA2729054C (en) 2008-06-26 2009-06-26 Antagonists of actriib and uses for increasing red blood cell levels

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2729098A Active CA2729098C (en) 2008-06-26 2009-06-26 Antagonists of activin-actriia and uses for increasing red blood cell levels
CA2729054A Active CA2729054C (en) 2008-06-26 2009-06-26 Antagonists of actriib and uses for increasing red blood cell levels

Country Status (10)

Country Link
EP (4) EP2318028B1 (OSRAM)
JP (8) JP5773868B2 (OSRAM)
KR (4) KR102024444B1 (OSRAM)
CN (2) CN102131515B (OSRAM)
AU (4) AU2009262968A1 (OSRAM)
CA (3) CA3049354A1 (OSRAM)
DK (1) DK2318028T3 (OSRAM)
ES (2) ES2791699T3 (OSRAM)
NZ (2) NZ602471A (OSRAM)
WO (2) WO2009158015A2 (OSRAM)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2426005T3 (es) 2004-07-23 2013-10-18 Acceleron Pharma Inc. Polipéptidos del receptor ACTRII, procedimientos y composiciones
EP3811965A1 (en) 2005-11-23 2021-04-28 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2599495A1 (en) 2007-02-01 2013-06-05 Acceleron Pharma, Inc. Activin-ActRIIa Antagonists and Uses for Treating or Preventing Breast Cancer
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
KR20200054317A (ko) 2007-02-09 2020-05-19 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HUE051137T2 (hu) 2008-08-14 2021-03-01 Acceleron Pharma Inc GDF-csapdák
WO2010083034A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
US8178488B2 (en) 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
ES2844123T3 (es) * 2009-08-13 2021-07-21 Acceleron Pharma Inc Uso combinado de trampas de GDF y activadores del receptor de la eritropoyetina para aumentar los niveles de glóbulos rojos
AU2015203400A1 (en) * 2009-08-13 2015-07-16 Acceleron Pharma Inc. Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
GR1007832B (el) * 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
US9809636B2 (en) * 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
EP2911682A4 (en) * 2012-10-24 2016-03-23 Celgene Corp METHOD FOR TREATING ANEMIA
US10195249B2 (en) * 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
MX362105B (es) * 2013-01-25 2019-01-04 Shire Human Genetic Therapies Folistatina en el tratamiento de distrofia muscular de duchenne.
EP3808778A1 (en) * 2014-04-18 2021-04-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
CN106795224B (zh) * 2014-06-04 2021-05-18 阿塞勒隆制药公司 用促滤泡素抑制素多肽治疗病症的方法和组合物
CN107135646B (zh) * 2014-06-13 2022-03-15 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
CN113683708A (zh) * 2015-04-06 2021-11-23 阿塞勒隆制药公司 单臂i型和ii型受体融合蛋白和其用途
PT3286206T (pt) 2015-04-22 2021-04-01 Biogen Ma Inc Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular
US10550170B2 (en) 2015-11-23 2020-02-04 Acceleron Pharma Inc. Methods for treating vascular eye disorders with actrii antagonists
WO2017177013A1 (en) 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
AU2017302282B2 (en) 2016-07-27 2024-07-25 Acceleron Pharma Inc. Methods and compositions for treating myelofibrosis
EP3523328A4 (en) 2016-10-05 2020-04-01 Acceleron Pharma Inc. VARIANT ACTRIIB PROTEINS AND USES THEREOF
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
WO2018089706A2 (en) * 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
WO2019094751A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
KR20200109330A (ko) 2018-01-12 2020-09-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
AU2019266314B2 (en) 2018-05-09 2025-05-15 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
JP7462907B2 (ja) * 2018-11-15 2024-04-08 三菱ケミカル株式会社 改変型アクチビンａ
AU2020334924A1 (en) * 2019-08-22 2022-04-07 The Regents Of The University Of California UBE3A for the treatment of Angelman syndrome
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
MX2024002711A (es) * 2021-09-03 2024-05-02 Laekna Therapeutics Shanghai Co Ltd Anticuerpos de receptor de activina tipo-2a (anti-acvr2a) y usos de estos.

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1265208A (en) 1915-09-07 1918-05-07 Edward C Kahn Liquid-fuel burner.
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
AU8761391A (en) * 1990-09-13 1992-04-15 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
NZ306767A (en) 1995-04-11 2000-03-27 Univ Johns Hopkins Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
WO1999010364A1 (en) 1997-08-29 1999-03-04 Human Genome Sciences, Inc. Follistatin-3
US6953662B2 (en) * 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3
US6468543B1 (en) * 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
JP2004526419A (ja) 2000-10-16 2004-09-02 フィロス インク． 抗体模倣物および他の結合タンパク質のためのタンパク質骨格
WO2002088171A2 (en) 2001-04-26 2002-11-07 Avidia Research Institute Combinatorial libraries of monomer domains
JP2005508141A (ja) * 2001-05-25 2005-03-31 セローノ ジェネティクス インスティテュート ソシエテ アニニム ヒトｃＤＮＡおよびタンパク質、ならびにそれらの使用
US6855344B2 (en) * 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
WO2005028517A2 (en) * 2003-05-09 2005-03-31 The General Hospital Corporation SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
US20070135336A1 (en) 2003-09-15 2007-06-14 De Kretser David Follistatin isoforms and uses thereof
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
ES2426005T3 (es) * 2004-07-23 2013-10-18 Acceleron Pharma Inc. Polipéptidos del receptor ACTRII, procedimientos y composiciones
US20060034831A1 (en) * 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
WO2006055689A2 (en) 2004-11-16 2006-05-26 Avidia Research Institute Protein scaffolds and uses thereof
EP3811965A1 (en) 2005-11-23 2021-04-28 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
US20080075692A1 (en) * 2006-05-09 2008-03-27 Perrine Susan P Methods for treating blood disorders
DK2043802T3 (da) * 2006-07-13 2012-10-08 Basf Se Bindemiddel indeholdende termoplastiske masser til fremstilling af metalliske støbelegemer
CN101522021B (zh) * 2006-07-21 2014-07-30 莱因实验室 醋酸钙的液体组合物
WO2008030367A2 (en) 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
US7547781B2 (en) * 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
UA116871C2 (uk) * 2006-12-18 2018-05-25 Акселерон Фарма Інк. СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
KR20200054317A (ko) 2007-02-09 2020-05-19 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
CA2699936A1 (en) * 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
DE102008016742B4 (de) * 2008-03-31 2010-01-14 Thyssenkrupp Presta Ag Lenksäule für ein Kraftfahrzeug

Also Published As

Publication number Publication date
EP2303917A4 (en) 2012-01-25
WO2009158015A3 (en) 2010-03-04
JP2014088438A (ja) 2014-05-15
EP3620795A1 (en) 2020-03-11
AU2016203098B2 (en) 2018-03-08
EP2303917B1 (en) 2020-11-11
WO2009158033A3 (en) 2010-04-01
KR20170038937A (ko) 2017-04-07
EP2318028B1 (en) 2020-02-19
CA2729098A1 (en) 2009-12-30
WO2009158033A2 (en) 2009-12-30
JP6643432B2 (ja) 2020-02-12
KR20210047374A (ko) 2021-04-29
JP2018184484A (ja) 2018-11-22
JP2015187180A (ja) 2015-10-29
CN102131515B (zh) 2017-06-27
JP2017036331A (ja) 2017-02-16
ES2852699T3 (es) 2021-09-14
WO2009158015A2 (en) 2009-12-30
CA2729054C (en) 2019-09-03
EP2303917A2 (en) 2011-04-06
EP2318028A4 (en) 2012-08-15
NZ590326A (en) 2013-05-31
NZ602471A (en) 2014-10-31
HK1245147A1 (zh) 2018-08-24
JP2011526626A (ja) 2011-10-13
CA2729054A1 (en) 2009-12-30
DK2318028T3 (da) 2020-05-04
AU2018204105A1 (en) 2018-06-28
AU2016203098A1 (en) 2016-06-02
EP3804746A1 (en) 2021-04-14
ES2791699T3 (es) 2020-11-05
CA2729098C (en) 2018-02-13
KR20190049912A (ko) 2019-05-09
JP2020041002A (ja) 2020-03-19
CN102131515A (zh) 2011-07-20
EP2318028A2 (en) 2011-05-11
JP2022023184A (ja) 2022-02-07
AU2009262968A1 (en) 2009-12-30
JP5773868B2 (ja) 2015-09-02
KR102024444B1 (ko) 2019-09-23
JP2019006805A (ja) 2019-01-17
KR20110031951A (ko) 2011-03-29
CN107252486A (zh) 2017-10-17
AU2020220046A1 (en) 2020-09-03
CN107252486B (zh) 2021-10-22

Similar Documents

Publication Publication Date Title
US20200255495A1 (en) Antagonists of actriib and uses for increasing red blood cell levels
US20220118049A1 (en) Methods for dosing an actriib antagonist and monitoring of treated patients
CA2729054C (en) Antagonists of actriib and uses for increasing red blood cell levels
US20200208124A1 (en) Isolated gdf trap polypeptide
CA2770822C (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
US20170327800A1 (en) Methods and compositions for treating ineffective erythropoiesis
HK40051596A (en) Antagonists of actriib and uses for increasing red blood cell levels
AU2021209153A1 (en) Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
AU2017204230A1 (en) Use of GDF traps to increase red blood cell levels
HK1156057B (en) Antagonists of actriib and uses for increasing red blood cell levels
HK1156057A (en) Antagonists of actriib and uses for increasing red blood cell levels

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200107

FZDE Discontinued

Effective date: 20220330

FZDE Discontinued

Effective date: 20220330